These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31004017)

  • 1. Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumab.
    Cook LBM; Demontis MA; Sagawe S; Witkover A; Melamed A; Turpin J; Dillon R; Haddow J; Marks AJ; Bangham CRM; Fields P; Taylor GP; Rowan AG
    Haematologica; 2019 Dec; 104(12):e566-e569. PubMed ID: 31004017
    [No Abstract]   [Full Text] [Related]  

  • 2. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
    Winsett FT; Lewis DJ; Duvic M
    Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mogamulizumab for the treatment of T-cell lymphoma.
    Makita S; Tobinai K
    Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological and clinical profile of mogamulizumab (POTELIGEO(®) Injection)].
    Kobatake C; Mizutani M; Amou M; Yurimoto S
    Nihon Yakurigaku Zasshi; 2013 Feb; 141(2):100-5. PubMed ID: 23391551
    [No Abstract]   [Full Text] [Related]  

  • 5. [Adult T-cell leukemia-lymphoma with severe hepatic damage and fluid retention successfully treated with mogamulizumab].
    Shodai A; Inoue H; Kamada Y; Fujino S; Tabuchi T; Arima N; Uchida Y; Hachiman M; Nakamura D; Yoshimitsu M; Ishitsuka K
    Rinsho Ketsueki; 2020; 61(6):612-616. PubMed ID: 32624533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma.
    Shima T; Kamezaki K; Higashioka K; Takashima S; Yoshimoto G; Kato K; Muta T; Takenaka K; Iwasaki H; Miyamoto T; Akashi K
    Intern Med; 2016; 55(13):1793-6. PubMed ID: 27374686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient.
    Taguchi M; Imaizumi Y; Sasaki D; Higuchi T; Tsuruda K; Hasegawa H; Taguchi J; Sawayama Y; Imanishi D; Hata T; Yanagihara K; Yoshie O; Miyazaki Y
    Ann Hematol; 2015 Apr; 94(4):693-5. PubMed ID: 25338968
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
    Sakamoto H; Itonaga H; Sawayama Y; Furumoto T; Fujioka M; Chiwata M; Toriyama E; Kasai S; Nakashima J; Horai M; Kato T; Sato S; Ando K; Taguchi J; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Miyazaki Y
    Hematol Oncol; 2020 Apr; 38(2):162-170. PubMed ID: 31922287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
    Mukai M; Maeda H; Narushima K; Mould DR; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
    Tobinai K; Takahashi T; Akinaga S
    Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).
    Kawano N; Yoshida N; Kawano S; Arakawa F; Miyoshi H; Yamada K; Nakashima K; Yoshida S; Kuriyama T; Tochigi T; Nakaike T; Shimokawa T; Yamashita K; Marutsuka K; Mashiba K; Kikuchi I; Ohshima K
    Intern Med; 2019 Aug; 58(15):2159-2166. PubMed ID: 30996180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
    Ureshino H; Kamachi K; Kimura S
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term remission with mogamulizumab monotherapy in a patient with refractory adult T-cell leukemia-lymphoma].
    Nakaya Y; Tsutsumi M; Fuseya H; Horiuchi M; Yoshimura T; Hayashi Y; Kanashima H; Nakao T; Yamane T
    Rinsho Ketsueki; 2018; 59(3):326-328. PubMed ID: 29618693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
    Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
    Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014).
    Kawano N; Kuriyama T; Sonoda KH; Yoshida S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
    Intern Med; 2016; 55(11):1439-45. PubMed ID: 27250049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide.
    Sekiguchi Y; Shimada A; Ichikawa K; Wakabayashi M; Sugimoto K; Kinoshita A; Suga Y; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2014; 7(9):6278-90. PubMed ID: 25337281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
    Satake A; Konishi A; Azuma Y; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Ito T; Ishii K; Nomura S
    Eur J Haematol; 2020 Dec; 105(6):704-711. PubMed ID: 32564395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
    de Lartigue J
    Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 20. Fatal pneumonia and viremia due to human parainfluenza virus type 1 in a patient with adult T-cell leukemia-lymphoma treated with mogamulizumab.
    Tamaki K; Kinjo T; Aoyama H; Tomoyose T; Nakachi S; Hanashiro T; Shimabukuro N; Tedokon I; Morichika K; Nishi Y; Taira N; Fujita J; Yoshimi N; Fukushima T; Masuzaki H
    J Infect Chemother; 2015 Nov; 21(11):820-3. PubMed ID: 26231316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.